Dyslipidaemia in rheumatological autoimmune diseases

Open Cardiovascular Medicine Journal

Volumn 5, Issue SPEC. ISSUE, 2011, Pages 64-75

  Toms, Tracey E ^a   Panoulas, Vasileios F ^a   Kitas, George D ^a,b  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Anti phospholipid syndrome; Autoimmune disease; Dyslipidaemia; Primary sjogrens syndrome; Rheumatoid arthritis; Systemic lupus erythematosus; Systemic sclerosis

Indexed keywords

CHOLESTEROL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; HIGH DENSITY LIPOPROTEIN; HYDROXYCHLOROQUINE; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOIMMUNE DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE COURSE; DYSLIPIDEMIA; HUMAN; INFLAMMATION; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 82855166058     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401105010064     Document Type: Review

References (154)

1. Kitas GD, Erb N. Tackling ischaemic heart disease in rheumatoid arthritis. Rheumatology 2003; 42: 607-13.
2. Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997; 145: 408-15.
3. Van Doornum S, McColl G, Wicks IP. Accelerated atherosclerosis: an extraarticular feature of rheumatoid arthritis? Arthritis Rheum 2002; 46: 862-73.
4. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
5. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002; 105: 1135-43.
6. Ross R, Glomset JA. Atherosclerosis and the arterial smooth muscle cell: Proliferation of smooth muscle is a key event in the genesis of the lesions of atherosclerosis. Science 1973; 180: 1332-9.
7. Loscalzo J. Endothelium, nitric oxide and atherosclerosis: From basic mechanisms to clinical implications. Circulation 2000; e21: 201.
8. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000; 87: 840-4.
9. Landmesser U, Dikalov S, Price SR, et al. Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest 2003; 111: 1201-9.
10. Tiefenbacher CP, Bleeke T, Vahl C, Amann K, Vogt A, Kubler W. Endothelial dysfunction of coronary resistance arteries is improved by tetrahydrobiopterin in atherosclerosis. Circulation 2000; 102: 2172-9.
11. Gerrity RG. The role of the monocyte in atherogenesis: II. Migration of foam cells from atherosclerotic lesions. Am J Pathol 1981; 103: 191-200.
12. Mehta JL, Li DY, Chen HJ, Joseph J, Romeo F. Inhibition of LOXI by statins may relate to upregulation of eNOS. Biochem Biophys Res Commun 2001; 289: 857-61.
13. Kugiyama K, Doi H, Motoyama T, et al. Association of remnant lipoprotein levels with impairment of endothelium-dependent vasomotor function in human coronary arteries. Circulation 1998; 97: 2519-26.
14. Kugiyama K, Motoyama T, Doi H, et al. Improvement of endothelial vasomotor dysfunction by treatment with alpha-tocopherol in patients with high remnant lipoprotein levels. J Am Coll Cardiol 1999; 33: 1512-8.
15. Schaich MP, John S, Langenfield MRW. Does lipoprotein (a) impair endothelial function. J Am Coll Cardio 1998; 31: 359-65.
16. Schillinger M, Mlekusch W, Haumer M, Sabeti S, Maca T, Minar E. Relation of small artery compliance and lipoprotein (a) in patients with atherosclerosis. Am J Hypertens 2002; 15: 980-85.
17. van Leuven SI, Franssen R, Kastelein JJ, Levi M, Stroes ESG, Tak PP. Systemic inflammation as a risk factor for atherothrombosis. Rheumatology 2008; 47: 3-7.
18. Wever RMF, Luscher TF, Cosentino F, Rabenlink TJ. Atherosclerosis and the two faces of endothelial nitric oxide synthase. Circulation 1998; 97: 108-12.
19. Letinger N. Oxidised phospholipids as modulators of inflammation in atehrosclerosis. Curr Opin Lipidol 2003; 14: 421-30.
20. Skalen K, Gustafsson M, Rydberg EK, et al. Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature 2002; 417: 750-4.
21. Massberg S, Brand K, Gruner S, et al. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J Exp Med 2002; 196: 887-96.
22. Henn V, Slupsky JR, Grafe M, et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-4.
23. Stary HC, Chandler AB, Glagov S, et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994; 89: 2462-78.
24. Toschi V, Gallo R, Lettino M, et al. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques. Circulation 1997; 95: 594-9.
25. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage infiltration in acute coronary syndromes. Implications for plaque rupture. Circulation 1994; 90: 775-8.
26. Symmons D, Turner G, Webb R, et al. The prevalence of rheumatoid arthritis in the United Kingdom: new estimates for a new century. Rheumatology 2002; 41: 793-800.
27. Pincus T, Callahan LF. Taking mortality in rheumatoid arthritis seriously-predictive markers, socioeconomic status and comorbidity. J Rheumatol 1986; 13: 841-5.
28. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008; 59: 1690-7.
29. Mutru O, Laasko M, Isomaki H, Koota K. Cardiovascular mortality in patients with rheumatoid arthritis. Br Med J 1989; 290: 1797-9.
30. Stevens RJ, Douglas KM, Saratzis AN, Kitas GD. Inflammation and atherosclerosis in rheumatoid arthritis. Expert Rev Mol Med 2005; 7: 1-24.
31. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. J Rheumatol 1997; 24: 445-51.
32. Wislowska M, Sypula S, Kowalick I. Echocardiographic findings, 24 hour electrocardiographic Holter monitoring in patients with rheumatoid arthritis according to Steinbrocker's criteria, functional index, value of Waaler-Rose titre and duration of disease. Clin Rheumatol 1998; 17: 377.
33. Aubry MC, Maradit-Kremers H, Reinalda MS, Crowson CS, Edwards WD, Gabriel SE. Differences in atherosclerotic coronary heart disease between subjects with and without rheumatoid arthritis. J Rheumatol 2007; 34: 937-42.
34. Maradit-Kremers H, Crowson CS, Nicola PJ, et al. Increased unrecognised coronary heart disease and sudden death in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005; 52: 402-11.
35. Panoulas VF, Douglas KM, Milionis HJ, et al. Prevalence and associations of hypertension and its control in patients with rheumatoid arthritis. Rheumatology 2007; 46: 1477-82.
36. Panoulas VF, Metsios GS, Pace AV, et al. Hypertension in rheumatoid arthritis. Rheumatology 2008; 47: 1286-98.
37. Metsios GS, Stavropoulos-Kalinglou A, Panoulas VF, et al. Asso-ciation of physical inactivity with increased cardiovascular risk in patients with rheumatoid arthritis. Eur J Cardiovascular Prev Rehab 2009; 16: 188-94.
38. Stavropoulos-Kalinglou A, Metsios GS, Panoulas VF, et al. Associations of obesity with modifiable risk factors for the development of cardiovascular disease in patients with rheumatoid arthritis. Ann Rheum Dis 2009; 68: 242-5.
39. Stavropoulos-Kalinoglou A, Metsios GS, Koutedakis Y, et al. Redefining overweight and obesity in rheumatoid arthritis patients. Ann Rheum Dis 2007; 66: 1316-21.
40. Lopez-Olivo MA, Gonzalez-Lopez L, Garcia-Gonzalez A, et al. Factors associated with hyperhomocysteinaemia in Mexican patients with rheumatoid arthritis. Scand J Rheumatol 2006; 35: 112-6.
41. Ingegnoli F, Fantini F, Giulio Favalli E, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: Effects of tumour necrosis factor-alpha blockade. J Autoimmun 2008; 31: 175-9.
42. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation 2001; 103: 1813-8.
43. Willerson JT, Ridker PM. Inflammation as a cardiovascular risk factor. Circulation 2004; 109: (21 suppl 1): 112-10.
44. Panoulas VF, Nikas SN, Smith JP, et al. Lymphotoxin 252A>G polymorphism is common and associates with myocardial infarction in patients with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1550-6.
45. Swanberg M, Lidman O, Padyukov L, et al. MHC2TA is associated with differential MHC molecule expression and suscepatbility to rheumatoid arthritis, multiple sclerosis and myocardial infarction. Nat Genet 2005; 37: 486-94.
46. Dessein PH, Joffe BI, Stanwix A, Botha AS, Moomal Z. The acute phase response does not fully predict the presence of insulin resistance and dyslipidaemia in inflammatory arthritis. J Rheumatol 2002; 29: 462-6.
47. Kavanaugh A. Dyslipoproteinaemia in a subset of patients with rheumatoid arthritis. Ann Rheum Dis 1994; 53: 551-2.
48. Park YB, Lee SK, Lee WK, et al. Lipid profiles in untreated patients with rheumatoid arthritis. J Rheumatol 1999; 26: 1701-4.
49. Peters MJ, Vis M, van Halm VP, et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 958-61.
50. van Halm VP, Nielen MM, Nurmohamed MT, et al. Lipids and inflammation: serial measurements of the lipid profile of blood donors who later developed rheumatoid arthritis. Ann Rheum Dis 2007; 66: 184-8.
51. Nurmohamed MT. Atherogenic lipid profiles and its management in patients with rheumatoid arthritis. Vasc Health Risk Manag 2007; 3: 845-52.
52. Yoo HW. Dyslipoproteinemia in patients with active rheumatoid arthritis: Effects of disease activity, sex, and menopausal status on lipid profiles. J Rheumatol 2004; 31: 1746-53.
53. Kelly CA. Extra-articular features of rheumatoid arthritis. Medicine 2002; 30: 48-9.
54. Choi HK, Seeger JD. Lipid profiles among US elderly with untreated rheumatoid arthritis--the Third National Health and Nutrition Examination Survey. J Rheumatol 2005; 32: 2311-6.
55. Toms TE, Symmons PM, Kitas GD. Dyslipidaemia in rheumatoid arthritis: the role of inflammation, drugs, lifestyle and genetic factors. Curr Vasc Pharm 2010; 8(3): 301-26.
56. Dursunoglu D, Evrengul H, Polat B, et al. Lp(a) lipoprotein and lipids in patients with rheumatoid arthritis: serum levels and relationship to inflammation. Rheumatol Int 2005; 25: 241-5.
57. Nurmohamed MT, Dijkmans BA. Dyslipidaemia, statins and rheumatoid arthritis. Ann Rheum Dis 2009; 68: 453-5.
58. Steiner G, Urowitz MB. Lipid profiles in patients with rheumatoid arthritis: mechanisms and the impact of treatment. Sem Arthritis rheum 2009; 38: 372-81.
59. Rantapaa-Dahlqvist S, Wallberg-Jonsson S, Dahlen G. Lipoprotein (a), lipids, and lipoproteins in patients with rheumatoid arthritis. Ann Rheum Dis 1991; 50: 366-8.
60. Svenson KL, Lithell H, Hallgren R, Selinus I, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity. Arch Intern Med 1987; 147: 1912-6.
61. Packard CJ, Ford I, Robertson M, et al. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation 2005; 112: 3058-65.
62. Contois JH, McConnell JP, Sethi AA, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem 2009; 55: 407-19.
63. Georgiadis AN, Voulgari PV, Argyropoulou MI, et al. Early Treatment Reduces the Cardiovascular Risk Factors in Newly Diagnosed Rheumatoid Arthritis Patients. Semin Arthritis Rheum 2008; 38: 13-9.
64. Garcia-Gomez C, Nolla JM, Valverde J, Gomez-Gerique JA, Castro MJ, Pinto X. Conventional Lipid Profile and Lipoprotein(a) Concentrations in Treated Patients with Rheumatoid Arthritis. J Rheumatol 2009; 36: 1365-70.
65. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation 1998; 97: 1837-47.
66. Kamanli A, Naziroglu M, Aydilek N, Hacievliyagil C. Plasma lipid peroxidation and antioxidant levels in patients with rheumatoid arthritis. Cell Biochem Funct 2004; 22: 53-7.
67. Stampfer MJ, Sacks FM, Salvini S, Willett WC, Hennekens CH. A prospective study of cholesterol, apolipoproteins, and the risk of myocardial infarction. N Engl J Med 1991; 325: 373-81.
68. Leu HB, Lin CP, Lin WT, Wu TC, Chen JW. Risk stratification and prognostic implication of plasma biomarkers in nondiabetic patients with stable coronary artery disease: the role of highsensitivity C-reactive protein. Chest 2004; 126: 1032-9.
69. Fernandez ML, Webb D. The LDL to HDL cholesterol ratio as a valuable tool to evaluate coronary heart disease risk. J Am Coll Nutr 2008; 27: 1-5.
70. van der Steeg WA, Boekholdt SM, Stein EA, et al. Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med 2007; 146: 640-8.
71. Choy E, Sattar N. Interpreting lipid levels in the context of highgrade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis 2009; 68: 460-9.
72. Bostom AG, Cupples LA, Jenner JL, et al. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 1996; 276: 544-8.
73. Danesh J, Collins R, Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000; 102: 1082-5.
74. Rouy D, Grailhe P, Nigon F, Chapman J, Angles-Cano E. Lipoprotein(a) impairs generation of plasmin by fibrin-bound tissue-type plasminogen activator. In vitro studies in a plasma milieu. Arterioscler Thromb 1991; 11: 629-38.
75. Berglund L, Anuurad E. Role of lipoprotein(a) in cardiovascular disease current and future perspectives. J Am Coll Cardiol 2008; 52: 132-4.
76. Maher VM, Brown BG, Marcovina SM, Hillger LA, Zhao XQ, Albers JJ. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995; 274: 1771-4.
77. Lee YH, Choi SJ, Ji JD, Seo HS, Song GG. Lipoprotein(a) and lipids in relation to inflammation in rheumatoid arthritis. Clin Rheumatol 2000; 19: 324-5.
78. Seriolo B, Paolino S, Sulli A, Fasciolo D, Cutolo M. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. Ann N Y Acad Sci 2006; 1069: 414-9.
79. Asanuma Y, Kawai S, Aoshima H, Kaburaki J, Mizushima Y. Serum lipoprotein(a) and apolipoprotein(a) phenotypes in patients with rheumatoid arthritis. Arthritis Rheum 1999; 42: 443-7.
80. Boerwinkle E, Leffert CC, Lin J, Lackner C, Chiesa G, Hobbs H. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest 1992; 90: 60.
81. Utermann G, Kraft HG, Menzel HJ, Hopferwieser T, Seitz C. Genetics of the quantitative Lp(a) lipoprotein trait. Hum Genet 1988; 78: 46.
82. Aldred S, Banks M, Kitas GD, Griffiths HR. Incrceased levels of oxidised LDL in the plasma of rheumatoid patients with cardiovascular disease: consequences for monocyte scavenger receptor uptake of LDL. Rheumatology 2001; 41: 69.
83. James MJ, van Reyk D, Rye KA, et al. Low density lipoprotein of synovial fliud in inflammatory joint disease is mildly oxidised. Lipids 1998; 33: 1115-21.
84. de Graaf J, Hak-Lemmers HL, Hectors MP, Demacker PN, Hendriks JC, Stalenhoef AF. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects. Arterioscler Thromb 1991; 11: 298-306.
85. Lamarche B, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, Despres JP. Associations of HDL2 and HDL3 subfractions with ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 1997; 17: 1098-105.
86. Hurt-Camejo E, Paredes S, Masana L, et al. Elevated levels of small, low-density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: possible contribution of phospholipase A2 to this atherogenic profile. Arthritis Rheum 2001; 44: 2761-7.
87. Popa C, van Tits LJH, Lemmers HLM, et al. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves highdensity lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. Ann.Rheum Dis 2009; 68: 868-72.
88. Schanberg LE, Sandborg C, Barnhart HX, et al. Premature atherosclerosis in pediatric systemic lupus erythematosus: Risk factors for increased carotid intima-media thickness in the atherosclerosis prevention in pediatric lupus erythematosus cohort. Arthritis Rheum 2009; 60: 1496-507.
89. El-Magadmi M, Bodill H, Ahmed Y, et al. Systemic lupus erythematosus: an independant risk factor for endothelial dysfunction in women. Circulation 2004; 110: 399-404.
90. Zeller CB, Appenzeller S. Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors. Curr Cardiol Rev 2008; 4: 116-22.
91. Ames PR, Margarita A, Alves JD. Antiphospholipid Antibodies and Atherosclerosis: Insights from Systemic Lupus Erythematosus and Primary Antiphospholipid Syndrome. Clin Rev Allergy Immunol 2008; 37: 29-35.
92. Frostegard J. SLE, atherosclerosis and cardiovascular disease. J Intern Med 2005; 257: 485-95.
93. Nuttall SL, Heaton S, Piper MK, Martin U, Gordon C. Cardiovascular risk in systemic lupus erythematosus--evidence of increased oxidative stress and dyslipidaemia. Rheumatology 2003; 42: 758-62.
94. Borba EF, Bonfa E. Dyslipoproteinemias in systemic lupus erythematosus: influence of disease, activity, and anticardiolipin antibodies. Lupus 1997; 6: 533-9.
95. de Carvalho JF, Bonfa E, Borba EF. Systemic lupus erythematosus and lupus dyslipoproteinemia. Autoimmun Rev 2008; 7: 246-50.
96. Chung CP, Oeser A, Solus J, et al. Inflammatory mechanisms affecting the lipid profile in patients with systemic lupus erythematosus. J Rheumatol 2007; 34: 1849-54.
97. Kashef S, Ghaedian MM, Rajaee A, Ghaderi A. Dyslipoproteinemia duering the active course of systemic lupus erythematosus in assocaition with anti-double-stranded DNA (anti-dsDNA) antibodies. Rheumatol Int 2006; 27: 235-41.
98. Asanuma Y, Chung CP, Oeser A, et al. Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol 2006; 33: 539-45.
99. Svenungsson E, Gunnarsson I, Fei GZ, Lundberg IE, Klareskog L, Frostegard J. Elevated triglycerides and low levels of high-density lipoprotein as markers of disease activity in association with upregulation of the tumour necrosis factor alpha/tumour necrosis factor receptor system in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 2533-40.
100. de Carvalho JF, Borba EF, Viana VS, Bueno C, Leon EP, Bonfa E. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus? Arthritis Rheum 2004; 50: 3610-5.
101. Ehnholm C, Aho K, Huttunen JK, et al. Effect of interferon on plasma lipoproteins and on the activity of postheparin plasma lipases. Arteriosclerosis 1982; 2: 68-73.
102. Reichlin M, Fesmire J, Quintero-Del-Rio AI, Wolfson-Reichlin M. Autoantibodies to lipoprotein lipase and dyslipidemia in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2957-63.
103. Ames PR, Alves J, Murat I, Isenberg DA, Nourooz-Zadeh J. Oxidative stress in systemic lupus erythematosus and allied conditions with vascular involvement. Rheumatology 1999; 38: 529-34.
104. McMahon M, Grossman J, Skaggs B, et al. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009; 60: 2428-37.
105. Love PE, Santoro SA. Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. Ann Intern Med 1990; 112: 682-98.
106. Wahl DG, Guillemin F, de Maistre E, Perret C, Lecompte T, Thibaut G. Risk for venous thrombosis related to antiphospholipid antibodies in systemic lupus erythematosus-a meta-analysis. Lupus 1997; 6: 467-73.
107. Lahita RG, Rivkin E, Cavanagh I, Romano P. Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum 1993; 36: 1566-74.
108. Vaarala O, Alfthan G, Jauhiainen M, Leirisalo-Repo M, Aho K, Palosuo T. Crossreaction between antibodies to oxidised lowdensity lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 1993; 341: 923-5.
109. Damoiseaux J, Jeyasekharan AD, Theunissen R, Tervaert JW. Cross-reactivity of IgM and IgG anticardiolipin antibodies with oxidised-low density lipoproteins. Ann N Y Acad Sci 2005; 1050: 163-9.
110. Kobayashi K, Kishi M, Atsumi T, et al. Circulating oxidised low density lipoprotein forms with B2-glycoprotein I: implication as an atherogenic autoantigen. J Lipid Res 2003; 10: 1196.
111. Chung CP, Oeser A, Raggi P, et al. Lipoprotein subclasses and particle size determined by nuclear magnetic resonance spectroscopy in systemic lupus erythematosus. Clin Rheumatol 2008; 27: 1227-33.
112. Hua X, Su J, Svenungsson E, et al. Dyslipidaemia and lipoprotein pattern in systemic lupus erythematosus (SLE) and SLE-related cardiovascular disease. Scand J Rheumatol 2009; 38: 184-9.
113. Ettinger WH, Goldberg AP, Applebaum-Bowden D, Hazzard WR. Dyslipoproteinaemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med 1987; 83: 503-8.
114. Forminga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R. Lipid and lipoprotein levels in premenopausal systemic lupus erythematosus patients. Lupus 2001; 10: 359-63.
115. Borba EF, Santos RD, Bonfa AE, et al. Lipoprotein (a) levels in systemic lupus erythematosus. J Rheumatol 1994; 21: 220-3.
116. Sari RA, Polat MF, Taysi S, Bakan E, Capoglu I. Serum lipoprotein (a) levels and its clinical significance in patients with systemic lupus erythematosus. Clin Rheumatol 2002; 21: 520-4.
117. Kawai S, Mizushima Y, Kaburaki J. Increased serum lipoprotein(a) levels in systemic lupus erythematosus with myocardial and cerebral infarctions. J Rheumatol 1995; 22: 1210-1.
118. Peros E, Geroldi D, Bugatti S, et al. Analysis of the apolipoprotein(a) size polymorphism in patients with systemic lupus erythematosus. Int J Mol Med 2005; 15: 661-5.
119. MacGregor AJ, Betteridge DJ, Isenberg DA. Serum lipoprotein (a) in systemic lupus erythematosus. Rheumatology 1990: 103-37.
120. Forminga F, Meco JF, Pinto X, Jacob J, Moga I, Pujol R. Lipid and lipoprotein levels in premenopausal systemic erythematosus patients. Lupus 2001; 10: 359-63.
121. Ettinger WHJr, Hazzard WR. Elevated apolipoprotein-B levels in corticosteroid-treated patients with systemic lupus erythematosus. J Clin Endo Metab 1988; 67: 425-8.
122. Hughes GR, Harris NN, Gharavi AE. The anticardiolipin syndrome. J Rheumatol 1986; 13: 486-9.
123. Ames PR, Sokoll K, Weston M, Margarita A, Brancaccio V. Atherosclerosis in primary antiphospholipid syndrome. Ann Rheum Dis 2004; 63: 610-1.
124. Vaarala O. Antiphospholipid antibodies and myocardial infarction. Lupus 1998; 7 Suppl 2: S132-4.
125. Zuckerman E, Toubi E, Shiran A, et al. Anticardiolipin antibodies and acute myocardial infarction in non-systemic lupus erythmatosus patients: a controlled prospective study. Am J Med 1996; 101: 381-6.
126. Ames PR, Margarita A, Sokoll KB, Weston M, Brancaccio V. Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data. Ann Rheum Dis 2005; 64: 315-7.
127. Soltesz P, Der H, Veres K, et al. Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction. Rheumatology 2008; 47: 1628-34.
128. Vlachoyiannopoulos PG, Kanellopoulos PG, Ioannidis JP, Tektonidou MG, Mastorakou I, Moutsopoulos HM. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology 2003; 42: 645-51.
129. Medina G, Casaos D, Jara LJ, et al. Increased carotid artery intimamedia thickness may be associated with stroke in primary antiphospholipid syndrome. Ann Rheum Dis 2003; 62: 607-10.
130. Vaudo G, Bocci EB, Shoenfeld Y, et al. Precocious intima-media thickening in patients with primary Sjogren's syndrome. Arthritis Rheum 2005; 52: 3890-7.
131. Lodde BM, Sankar V, Kok MR, Leakan RA, Tak PP, Pillemer SR. Serum lipid levels in Sjogren's syndrome. Rheumatology 2006; 45: 481-4.
132. Gerli R, Bartoloni BE, Vaudo G, Marchesi S, Vitali C, Shoenfeld Y. Traditional cardiovascular risk factors in primary Sjogren's syndrome--role of dyslipidaemia. Rheumatology 2006; 45: 1580-1.
133. Cutolo M, Sulli A, Secchi ME, Paolino S, Pizzorni C. Nailfold capillaroscopy is useful for the diagnosis and follow-up of autoimmune rheumatic diseases. A future tool for the analysis of microvascular heart involvement? Rheumatology 2006; 45 Suppl 4: iv43-6.
134. Secchi ME, Sulli A, Pizzorni C, Cutolo M. Nailfold capillaroscopy and blood flow laser-doppler analysis of the microvascular damage in systemic sclerosis: preliminary results. Reumatismo 2009; 61: 34-40.
135. Ho M, Veale D, Eastmond C, Nuki G, Belch J. Macrovascular disease and systemic sclerosis. Ann Rheum Dis 2000; 59: 39-43.
136. Bryan C, Howard Y, Brennan P, Black C, Silman A. Survival following the onset of scleroderma: results from a retrospective inception cohort study of the patients population. Br J Rheumatol 1996; 35: 1122-6.
137. Fowkes FGR, Housley E, Cawood EHH, Macintyre CCA, Ruckley CV, Prescott RJ. Edinburgh artery study: Prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol 1991; 20: 384-92.
138. Veale DJ, Collidge TA, Belch JJ. Increased prevalence of symptomatic macrovascular disease in systemic sclerosis. Ann Rheum Dis 1995; 54: 853-5.
139. Hettema ME, Zhang D, de Leeuw K, Steinstra Y, Kallenberg CG, Bootsma H. Early atherosclerosis in systemic sclerosis and its relation to disease or traditional risk factors. Arthritis Res Ther 2008; 10: R49.
140. Szucs G, Timar O, Szekanecz Z, et al. Endothelial dysfunction precedes atherosclerosis in systemic sclerosis relevance for prevention of vascular complications. Rheumatology 2007; 46: 759-62.
141. Cypiene A, Laucevicius A, Venalis A, et al. The impact of systemic sclerosis on arterial wall stiffness parameters and endothelial function. Clin Rheumatol 2008; 27: 1517-22.
142. Cardillo C, Campia U, Kilcoyne CM, Bryant MB, Panza JA. Improved endothelin-dependant vasodilatation after blockade of endothelin receptors in patients with essential hypertension. Circulation 2002; 105: 452-6.
143. Kotyla PJ, Lewicki M, Kucharz EJ. Hypothyroidism contributes to increased triglyceride levels among patients with systemic sclerosis. J Rheumatol 2006; 33: 827.
144. Kodera M, Hayakawa I, Komura K, et al. Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations. J Rheumatol 2005; 32: 629-36.
145. Bruckdorfer KR, Hillary JB, Bunce T, Vancheeswaran R, Black CM. Increased susceptibility to oxidation of low-density lipoproteins isolated from patients with systemic sclerosis. Arthritis Rheum 1995; 38: 1060-7.
146. Lippi G, Caramaschi P, Montaganana M, Salvagno GL, Volpe A, Guidi G. Lipoprotein (a) and the lipid profile in patients with systemic sclerosis. Clin Chimica Acta 2006; 364: 345-8.
147. Andersen GA, Caidahi K, Kazzam E, et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: Findings with the soluble adhesion molecules E-selectin, intracellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 2001; 43: 1085-93.
148. Gruschwitz MS, Hornstein OP, von Den Driesch P. Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 1995; 38: 184-9.
149. Hodis HN, Quismorio FP, Wickham E, Blankenhorn DH. The lipid, lipoprotein, and apolipoprotein effects of hydroxychloroquine in patients with systemic lupus erythematosus. J Rheumatol 1993; 20: 661-5.
150. Popa C, van den Hoogen FH, Radstake TR, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. Ann Rheum Dis 2007; 66: 1503-7.
151. Tam LS, Tomlinson B, Chu TT, Li TK, Li EK. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol 2007; 26: 1495-8.
152. Munro R, Morrison E, McDonald AG, Hunter JA, Madhok R, Capell HA. Effect of disease modifying agents on the lipid profile of patients with rhuematoid arthritis. Ann Rheum Dis 1997; 56: 374-7.
153. Tam LS, Gladman DD, Hallatt DC, Rahman P, Urowitz MB. Effect of antimalarial agents on the fasting lipid profile in systemic lupus erythematosus. J Rheumatol 2000; 27: 2142-5.
154. Soubrier M, Jouanel P, Mathieu S, et al. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. Joint Bone Spine 2008; 75: 22-4.